UK Votes To Leave The EU – What's Next For The Life Sciences?
This article was originally published in The Gray Sheet
Executive Summary
The UK government will have to engage in many years of bargaining over its future relationship with the EU, whether as part of the single market or under the umbrella of the World Trade Organization, as well with the countries with which the EU has trade agreements. What this means precisely for the device industry and oversight of devices in the UK remains to be seen.
You may also be interested in...
EU Countries Offered Funding To Contribute to African Regulatory Strengthening
Training projects are intended to strengthen the African regulatory environment, boost the capacity of the African Medicines Agency, facilitate regulatory reliance, and increase joint new drug assessments.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.